Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, B-Cell, Marginal Zone 15Lymphoma, Mantle-Cell 10Lymphoma, Large B-Cell, Diffuse 8Lymphoma 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Part 1:r/r B-cell Malignancies 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma × orelabrutinib × Lymphoid × Clear all
NCT07441993 2026-03-02

MZL-IIT-O

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
45 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT06015464 2023-08-29

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

The First Affiliated Hospital with Nanjing Medical University

Unknown
81 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡